Skip to main content
. Author manuscript; available in PMC: 2021 Jun 26.
Published in final edited form as: Mod Pathol. 2020 Jul 1;33(11):2221–2232. doi: 10.1038/s41379-020-0606-0

Figure 4.

Figure 4.

Somatic mutations and copy number alterations identified by Memorial Sloan Kettering Mutation Profiling of Actionable Cancer Targets next-generation sequencing assay in 37 primary triple-negative breast carcinomas by PD-L1 status of stromal tumor-infiltrating immune cells. Cases are represented in columns, and genes are displayed in rows. Alteration types are color-coded according the legend. Somatic mutations in CBFB were significantly associated with PD-L1-negative stromal tumor-infiltrating immune cells in primary triple-negative breast carcinoma on univariate analysis with Fisher exact test (P = .03), but no longer significant after adjusting for multiple comparisons (P = .32). Values written in red denote significant P < .05.